Status:
UNKNOWN
The Effects of Growth Hormone Treatment Discontinuation in Adults on Metabolic Profile, Body Composition and Quality Of Life (GAMBOL Study)
Lead Sponsor:
University Hospital Birmingham
Conditions:
Adult Growth Hormone Deficiency
Eligibility:
All Genders
25-90 years
Brief Summary
Background Growth hormone (GH) is a hormone produced by the pituitary gland which sits at the base of the brain. In adults, GH plays an important role in keeping the bones and muscles healthy, and in ...
Detailed Description
1. BACKGROUND Growth hormone deficiency (GHD) in adults is caused by decreased secretion of growth hormone (GH) from the pituitary gland (1, 2). This condition is usually caused by a tumour, surge...
Eligibility Criteria
Inclusion
- Patients aged 25 years and over with GHD.
- GHD previously confirmed by a validated test as per guideline (7).
- On GH replacement therapy for 5 years or longer.
- Able to provide informed written consent.
Exclusion
- Patients with poorly controlled diabetes (defined as having an HbA1c of \>7%), poorly controlled hyperlipidaemia and severe cardiovascular disease.
- Patients receiving treatment for low BMD or deemed to be requiring treatment for low BMD during baseline screening.
- Patients who are unable to provide informed written consent.
Key Trial Info
Start Date :
July 28 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2025
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT05979480
Start Date
July 28 2023
End Date
November 30 2025
Last Update
August 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Birmingham NHS Foundation Trust
Birmingham, West Midlands, United Kingdom, B15 2GW